These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 7761092)

  • 1. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
    Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
    Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
    Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
    Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
    Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers.
    Clark GJ; Kinch MS; Gilmer TM; Burridge K; Der CJ
    Oncogene; 1996 Jan; 12(1):169-76. PubMed ID: 8552388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TC21 and Ras share indistinguishable transforming and differentiating activities.
    Graham SM; Oldham SM; Martin CB; Drugan JK; Zohn IE; Campbell S; Der CJ
    Oncogene; 1999 Mar; 18(12):2107-16. PubMed ID: 10321735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors.
    Prendergast GC; Davide JP; Lebowitz PF; Wechsler-Reya R; Kohl NE
    Cancer Res; 1996 Jun; 56(11):2626-32. PubMed ID: 8653708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transformation-selective apoptotic program triggered by farnesyltransferase inhibitors requires Bin1.
    DuHadaway JB; Du W; Donover S; Baker J; Liu AX; Sharp DM; Muller AJ; Prendergast GC
    Oncogene; 2003 Jun; 22(23):3578-88. PubMed ID: 12789266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells.
    Cox AD; Brtva TR; Lowe DG; Der CJ
    Oncogene; 1994 Nov; 9(11):3281-8. PubMed ID: 7936652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal transduction elements of TC21, an oncogenic member of the R-Ras subfamily of GTP-binding proteins.
    Movilla N; Crespo P; Bustelo XR
    Oncogene; 1999 Oct; 18(43):5860-9. PubMed ID: 10557073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.
    Lebowitz PF; Prendergast GC
    Oncogene; 1998 Sep; 17(11 Reviews):1439-45. PubMed ID: 9779989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity.
    Leftheris K; Kline T; Vite GD; Cho YH; Bhide RS; Patel DV; Patel MM; Schmidt RJ; Weller HN; Andahazy ML; Carboni JM; Gullo-Brown JL; Lee FY; Ricca C; Rose WC; Yan N; Barbacid M; Hunt JT; Meyers CA; Seizinger BR; Zahler R; Manne V
    J Med Chem; 1996 Jan; 39(1):224-36. PubMed ID: 8568812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guanine nucleotide exchange factors: activators of Ras superfamily proteins.
    Overbeck AF; Brtva TR; Cox AD; Graham SM; Huff SY; Khosravi-Far R; Quilliam LA; Solski PA; Der CJ
    Mol Reprod Dev; 1995 Dec; 42(4):468-76. PubMed ID: 8607978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
    Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
    Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
    Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
    J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
    Kelloff GJ; Lubet RA; Fay JR; Steele VE; Boone CW; Crowell JA; Sigman CC
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):267-82. PubMed ID: 9107432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vav cooperates with Ras to transform rodent fibroblasts but is not a Ras GDP/GTP exchange factor.
    Bustelo XR; Suen KL; Leftheris K; Meyers CA; Barbacid M
    Oncogene; 1994 Aug; 9(8):2405-13. PubMed ID: 8036025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic activation of human R-ras by point mutations analogous to those of prototype H-ras oncogenes.
    Saez R; Chan AM; Miki T; Aaronson SA
    Oncogene; 1994 Oct; 9(10):2977-82. PubMed ID: 8084601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.